KAS
HRMY icon

Kestra Advisory Services’s Harmony Biosciences HRMY Stock Holding History

Kestra Advisory Services’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,245
Closed -$46.6K – 3683
2025
Q4 		$46.6K Buy
+1,245
New +$40.9K ﹤0.01% 3992

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Kestra Advisory Services's HRMY Position: Q1 2026 in Review

Kestra Advisory Services sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 1,245 shares — an estimated $46.6K sold.

Kestra Advisory Services first reported a position in HRMY in Q4 2025 and held it in 1 quarter. The position peaked at $46.6K in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Kestra Advisory Services reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 1,245 Harmony Biosciences shares in Q1 2026, an estimated $46.6K.
  • Kestra Advisory Services first reported a position in Harmony Biosciences in Q4 2025 and held it in 1 quarter.
  • Kestra Advisory Services's Harmony Biosciences position peaked at $46.6K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.